Breast cancer drug combo trial ends early after only 8 patients
NCT ID NCT06851442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug combination (TQB3912, fulvestrant, and TQB3616) in people with advanced HR-positive, HER2-negative breast cancer. The goal was to find the best dose and see if the treatment shrank tumors or slowed cancer growth. The trial was stopped early after enrolling only 8 participants, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuzhou First General Hospital
Fuzhou, Fujian, 350009, China
-
Guizhou Medical University Affiliated Cancer Hospital Co., Ltd
Guiyang, Guizhou, 550001, China
-
Guizhou Provincial People's Hospital
Guiyang, Guizhou, 550002, China
-
Harbin Medical University Cancer
Harbin, Heilongjiang, 150000, China
-
Liaoning Cancer Hospital
Shenyang, Liaoning, 110000, China
-
Meizhou peoples Hospital
Meizhou, Guangdong, 514000, China
-
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, 315000, China
-
Quanzhou First Hospital
Quanzhou, Fujian, 362000, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, 030000, China
-
Taizhou Central Hospital (Taizhou University Affiliated Hospital)
Taizhou, Zhejiang, 31800, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233000, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shaanxi, 710061, China
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, 300202, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300202, China
-
Xinjiang Medical University Affiliated Cancer Hospital
Ürümqi, Xinjiang, 830000, China
-
Yongzhou Central Hospital
Yongzhou, Hunan, 425002, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?